Microbially-produced peptides having potential application to the prevention of dental caries

International Journal of Antimicrobial Agents

Volumn 9, Issue 2, 1997, Pages 95-105

  Chikindas, M L ^c   Novak J ^a   Caufield, P W ^a   Schilling, K ^d   Tagg, J R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Louisiana State University Health Sciences Center at Shreveport   (United States)

^d UNILEVER RESEARCH   (United Kingdom)

Author keywords

Antibacterial peptides; Bacteriocin; Dental caries; Microbial interference

Indexed keywords

PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT;

DENTAL CARIES; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOOTH PLAQUE;

EID: 0030846210     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00040-X     Document Type: Article

References (122)

1. Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington (DC): US Department of Health and Human Services, Public Health Service, 1991. DHHS Publication No. (PHS) 91-50212.
2. Douglass CW, Day JM. Cost and payment of dental services in the USA. J Dent Edu 1979;43:330-48.
3. Gotowka TD. Economic growth of the dental health profession: comparisons with other health care sectors. J Am Dent Assoc 1985;110:179-87.
4. Federal Health Care Financing Administration. J Am Dent Assoc 1992;123:18.
5. Anderson MH, Bales DJ, Omnell KA. Modern management of dental caries: the cutting edge is not the dental bur. J Am Dent Assoc 1993;124:36-44.
6. Loesche W. Dental Caries: A Treatable Infection. Springfield (IL): Thomas, 1982.
7. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891-4.
8. Longman LP, Pearce KP, McGowan P, Hardy P, Martin MV. Antibiotic-resistant oral streptococci in dental patients susceptible to infective endocarditis. J Med Microbiol 1991;34:33-7.
9. Knox KW, Hunter N. The role of oral bacteria in the pathogenesis of infective endocarditis. Aust Dent J 1991;36:286-92.
10. Bigl P, Pavek V, Brezinova L. Eikenella corrodens infection of the oral cavity as a cause of bacterial endocarditis. Czech Med 1990;13:38-42.
11. Chen CKC, Dunford RG, Reynolds HS, Zambon JJ. Eikenella corrodens in the human oral cavity. J Periodontol 1989;60:611-6.
12. Burnette-Curley D, Wells V, Viscount H. FimA, a major virulence factor associated with Streptococcus parasanguis endocarditis. Infect Immun 1995;63:4669-74.
13. Jacobs JA, Stappers JL, Sels JP. Endocarditis due to Streptococcus oralis in a patient with a colon tumour. Eur J Clin Microbiol Infect Dis 1995;14:557-8.
14. Hardy KG. Colicinogeny and related phenomena. Bacteriol Rev 1975;39:464-515.
15. Donoghue HD, Tyler JE. Antagonisms amongst streptococci isolated from the human oral cavity. Arch Oral Biol 1975;20:381-7.
16. Holmberg K, Hallander HO. Production of bactericidal concentrations of hydrogen peroxide by Streptococcus sanguis. Arch Oral Biol 1973;18:423-34.
17. Ikeda T, Kurita T, Hirasawa M. Supression of Streptococcus sobrinus 6715 (g) in plaques by Streptococcus mutans 32K (c). J Oral Pathol 1988;17:471-4.
18. Tagg JR, Dajani AS, Wannamaker LW. Bacteriocins of Gram-positive bacteria. Bacteriol Rev 1976;40:722-56.
19. Reeves P. The bacteriocins. Bacteriol Rev 1965;29:24-45.
20. Jung G, Sahl HG. Nisin and Novel Lantibiotics. Leiden, The Netherlands: ESCOM Science, 1991.
21. James R, Lazdunski C, Pattus F. Bacteriocins, Microcins and Lantibiotics. Heidelberg: Springer-Verlag, 1992.
22. Kolter R, Moreno F. Genetics of ribosomally synthesized peptide antibiotics. Ann Rev Microbiol 1992;46:141-63.
23. Ray B, Daeschel M. Food Biopreservatives of Microbial Origin. Boca Raton (FL): CRC Press, 1992.
24. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 1993;12:39-86.
25. Jack RW, Tagg JR, Ray B. Bacteriocins of Gram-positive bacteria. Microbiol Rev 1995;59:171-200.
26. Sahl HG, Jack RW, Bierbaum G. Lantibiotics: biosynthesis and biological activities of peptides with unique post-translational modifications. Eur J Biochem 1995;230:827-53.
27. Song HY, Cramer WA. Membrane topography of Co1E1 gene products: the immunity protein. J Bacteriol 1991;173:2935-43.
28. Geli V, Lazdunski C. Ana-helical hydrophobic hairpin as a specific determinant in protein-protein interaction occuring in Escherichia coil colicin A and B immunity systems. J Bacteriol 1992;174:6432-7.
29. Zhang YL, Cramer WA. Intramembrane helix-helix interactions as the basis of inhibition of the colicin El ion channel by its immunity protein. J Biol Chem 1993;268:1076-10184.
30. Venema K, Haverkort RE, Abee T. Mode of action of LciA, the lactococcin A immunity protein. Mol Microbiol 1994;14:521-32.
31. Abee T, Krockel L, Hill C. Bacteriocins: modes of action and potentials in food preservation and control of food poisoning. Int J Food Microbiol 1995;28:169-85.
32. Jung G. Lantibiotics-ribosomally synthesized biologically active polypeptides containing sulfide bridges and α-β-didehydroamino acids. Angew Chem Int Ed Engl 1991;30:1051-68.
33. Gross E, Morell JL. The structure of nisin. J Am Chem Soc 1971;93:4634-5.
34. Gross E, Morell JL. The presence of dehydroalanine in the antibiotic nisin and its relationship to activity. J Am Chem Soc 1967;89:2791-2.
35. Gao FH, Abee T, Konings WN. Mechanism of action of the peptide antibiotic nisin in liposomes and cytochrome c oxidase containing proteoliposomes. Appl Envir Microbiol 1991;57:2164-70.
36. Konisky J. Colicins and other bacteriocins with established modes of action. Ann Rev Microbiol 1982;36:125-44.
37. Ghosh P, Mel SF, Stroud RM. The domain structure of the ion channel-forming protein colicin Ia. Nature Struc Biol 1994;1:597-604.
38. Sansom MSP. The fine art of pore formation. Nature Struct Biol 1994;1:563-7.
39. Weerkamp A, Bongaerts-Larik L, Vogels GD. Bacteriocins as factors in the in vitro interaction between oral streptococci in plaque. Infect Immun 1977;16:773-80.
40. van Belkum MI, Kok J, Venema G. The bacteriocin lactococcin A specifically increases permeability of lactococcal cytoplasmic membranes in a voltage-independent protein-mediated manner. J Bacteriol 1991;173:7934-41.
41. Chikindas ML, Garcera MJG, Driessen AJM. Pediocin PA-1, a bacteriocin from Pediococcus acidilactici PAC1.0, forms hydrophilic pores in the cytoplasmic membrane of target cells. Appl Environ Microbiol 1993;59:3577-84.
42. Chikindas ML, Novak J, Driessen AJM, Konings WN, Schilling KM, Caufield PW. Mutacin II, a bactericidal lantibiotic from Streptococcus mutans. Antimicrob Agents Chemother 1995;39:2656-60.
43. Jakes K. The mechanism of action of colicin E2, colicin E3, and colicin DF13. In: van Heyninger S, Cohen P, editors. The Molecular Actions of Toxins and Viruses. North Holland: Elsevier, 1982:131-167.
44. Håvarstein LS, Coomaraswamy G, Morrison DA. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc Natl Acad Sci USA 1995;92:11140-4.
45. Rutter RR, Ruefenacht WG, Chamberlain CR, Thomassen PR, Rose M, Scrivener CA. The principle of bacterial antagonism applied as an aid in the reduction of dental caries. J Dent Res 1961;40:1112-5.
46. Cuppels DA, Hanson RS, Kelman A. Isolation and characterization of a bacteriocin produced by Pseudomonas solanacearum. J Gen Microbiol 1978;109:295-303.
47. Blackburn P, Polak J, Gusik SA, Rubino SD. Nisin composition for use as enhanced, broad range bactericides. US Patent No. 5135910, 1991.
48. Henderson JT, van Wassenaar P. New peptide corresponding to the sequence of a bacteriocin used for inhibiting bacteria such as Listeria monocytogenes. European Patent No. 453719, 1991.
49. Gibbons RJ. Formation and significance of bacterial polysaccharides in caries aetiology. Caries Res 1968;2:164-71.
50. Hamada S, Slade HD. Biology, immunology and cariogenicity of Streptococcus mutans. Microbiol Rev 1980;44:331-84.
51. Loesche WJ. Role of Streptococcus mutans in human dental decay. Microbiol Rev 1986;50:353-80.
52. Tagg JR. BLIS production in the genus Streptococcus. In: James R, Lazdundki C, Pattus F, editors. Bacteriocins, Microcins and Lantibiotics. Heidelberg: Springer-Verlag, 1992:417-420.
53. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993;12:221-38.
54. Kelstrup J, Gibbons RJ. Bacteriocins from human and rodent streptococci. Arch Oral Biol 1969;14:251-8.
55. Hamada S, Ooshima T. Production and properties of bacteriocins (mutacins) from Streptococcus mutans. Arch Oral Biol 1975;20:641-8.
56. Hamada S, Ooshima T. Inhibitory spectrum of a bacteriocin-like substance (mutacin) produced by some strains of Streptococcus mutans. J Dent Res 1975;54:140-5.
57. Whiley RA, Russell RRB, Hardie JM, Beighton D. Streptococcus downei sp.nov. for strains previously described as Streptococcus mutans serotype h. Int J Systemat Bacteriol 1988;38:25-9.
58. Rogers AH. Bacteriocinogeny and the properties of some bacteriocins of Streptococcus mutans. Arch Oral Biol 1976;21:99-104.
59. Fabio U, Bondi M, Manicardi G, Messi P, Neglia R. Production of bacteriocin-like substances by human oral streptococci. Microbiologica 1987;10:363-70.
60. Parrot M, Caufield PW, Lavoie MC. Preliminary characterization of four bacteriocins from Streptococcus mutans. Can J Microbiol 1990;36:123-30.
61. Parrot M. Dréan MF, Trehan L, Lavoie MC. Incidence of bacteriocinogeny among fresh isolates of Streptococcus mutans. Can J Microbiol 1990;36:507-9.
62. Baca P, Liebana J, Piedrola G. Epidemiological application of a new bacteriocin typing scheme for Streptococcus mutans. Community Dent Oral Epidemiol 1990;18:194-6.
63. van der Hoeven JS, Rogers AH. Stability of the resident microflora and the bacteriocinogeny of Streptococcus mutans as factors affecting its establishment in specific pathogen-free rats. Infect Immun 1979;23:206-13.
64. Beighton D, Hayday H, Walker J. The acquisition of Streptococcus mutans by infant monkeys (Macaca fascicularis) and its relationship to the initiation of dental caries. J Gen Microbiol 1982;128:1881-92.
65. Fukushima H, Fukushima S, Umemoto T, Fukuhara H, Sagawa H. Purification and chemical analysis of a bacteriocin from the oral bacterium Streptococcus mutans Rm-10. Arch Oral Biol 1982;27:721-7.
66. Fukushima H, Kelstrup J, Fukushima S, Umemoto T, Sagawa H. Isolation, partial purification and preliminary characterization of a bacteriocin from Streptococcus mutans Rm-10. Antonie van Leeuwenhoek 1983;49:41-50.
67. Fukushima H, Kelstrup J, Fukushima S, Umemoto T, Kaibori A, Sagawa H. Characterization and mode of action of a purified bacteriocin from the oral bacterium Streptococcus mutans Rm-10. Arch Oral Biol 1985;30:229-34.
68. Tsukamoto Y, Fukutani S, Takayama Y, Fukushima H, Sagawa H, Mori M. Characterization of leukocyte chemotactic activity of bacteriocin from Streptococcus mutans Rm-10. Inflammation 1990;14:561-9.
69. Ikeda T, Iwanami T, Hirasawa M, Watanabe C, McGhee JR, Shiota T. Purification and certain properties of a bacteriocin from Streptococcus mutans. Infect Immun 1982;35:861-8.
70. Takada K, Ikeda T, Mitsui I, Shiota T. Mode of inhibitory action of a bacteriocin produced by Streptococcus mutans C3603. Infect Immun 1984;44:370-8.
71. Ikeda T, Koulourides T, Kurita T, Housch T, Hirasawa M. Anti-dental caries effect in rats and man of a bacteriocin purified from the oral bacterium Streptococcus mutans C3603. Arch Oral Biol 1985;30:381-4.
72. Ooshima T, Yasufuku Y, Izumitani A, Sumi N, Iwanami T. Effect of mutacin administration on Streptococcus mutans-induced dental caries in rats. Microbiol Immunol 1985;29:1163-73.
73. Hamada S, Imanishi H, Ooshima T. Isolation and mode of action of a cell-free bacteriocin (mutacin) from serotype g Streptococcus mutans MT3791. Zentralbl Bakteriol Mikrobiol Hyg Ser A 1986;261:287-98.
74. Delisle AL. Production of bacteriocins in a liquid medium by Streptococcus mutans. Antimicrob Agents Chemother 1975;8:707-12.
75. Delisle AL. Activity of two Streptococcus mutans bacteriocins in the presence of saliva, levan and dextran. Infect Immun 1976;13:619-26.
76. Delisle AL. Properties of mutacin b, an antibacterial substance produced by Streptococcus mutans strain BHT. Microbios 1986;46:21-8.
77. Parrot M, Charest M, Lavoie MC. Production of mutacin-like substances by Streptococcus mutans. Can J Microbiol 1989;35:366-72.
78. Morency H, Lavoie MC. Effects of dietary carbohydrates on mutacin production and activity. Microbios 1991;67:35-46.
79. Caufield PW, Childers NK, Allen DN, Hansen JB. Distinct bacteriocin groups correlate with different groups of Streptococcus mutans plasmids. Infect Immun 1985;48:51-6.
80. Caufield PW, Childers NK, Allen DN. Plasmids in Streptococcus mutans: usefulness as epidemiological markers and association with mutacins. In: Hamada S, Michalek S, Kiyono H, Menaker L, McGhee J, editors. Molecular Microbiology and Immunobiology of Streptococcus mutans. New-York: Elsevier, 1986:217-223.
81. Morency H, Trahan L, Lavoie MC. Preliminary grouping of mutacins. Can J Microbiol 1995;41:826-31.
82. Caufield PW, Shah GR, Hollingshead SK. Use of transposon Tn916 to inactivate and isolate a mutacin-associated gene from Streptococcus mutans. Infect Immun 1990;58:4126-35.
83. Caufield PW, Shah GR, Hollingshead SK, Parrot M, Lavoie MC. Evidence that mutacin II production is not mediated by a 5.6-kb plasmid in Streptococcus mutans. Plasmid 1990;24:110-8.
84. Novák J, Caufield PW, Miller EJ. Isolation and characterization of a novel lantibiotic mutacin from Streptococcus mutans. J Bacteriol 1994;176:4316-20.
85. Novák J, Kirk M, Caufield PW, Barnes S, Morrison K, Baker J. Detection of modified amino acids in lantibiotic peptide mutacin II by chemical derivatization followed by electrospray ionization mass spectroscopic analysis. Anal Biochem 1996;236:358-60.
86. Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 1984;44:141-4.
87. Loyola-Rodriguez JP, Morisaki I, Kitamura K, Hamada S. Purification and properties of extracellular mutacin, a bacteriocin from Streptococcus sobrinus. J Gen Microbiol 1992;138:269-74.
88. Kurita T, Hirasawa M. Biological and biochemical characterization of novel lipid-like antibacterial substances (mutalipocins) produced by Streptococcus mutans strain 32K. J Gen Microbiol 1988;134:213-20.
89. James SM, Tagg JR. A search within the genera Streptococcus, Enterococcus and Lactobacillus for organisms inhibitory to mutans streptococci. Microbial Ecol Health Dis 1988;1:153-62.
90. Simmonds RS, Naidoo J, Jones CL, Tagg JR. The streptococcal bacteriocin-like inhibitory substance, zoocin A, reduces the proportion of Streptococcus mutans in an artificial plaque. Microbial Ecol Health Dis 1995;8:281-92.
91. Simmonds RS, Simpson WJ, Tagg JR. Cloning and sequence analysis of zoo A, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. Gene 1997;189:255-61.
92. Simmonds RS, Pearson L, Kennedy RC, Tagg JR. Mode of action of a lysostaphin-like bacteriolytic agent produced by Streptococcus zooepidemicus strain 4881. Appl Environ Microbiol 1996;62:4536-41.
93. Skilton CJ, Tagg JR. The production by Streptococcus sanguis of bacteriocin-like inhibitory substances (BLIS) with activity against Streptococcus rattus. Microbial Ecol Health Dis 1992;5:219-26.
94. Shurin SB, Socransky SS, Sweeney E, Stossal TP. A neutrophil disorder induced by capnocytophaga, a dental microorganism. New Engl J Med 1979;301:849-54.
95. Slots J, Genco RJ. Microbial pathology. Black-pigmented Bacteroides species. Capnocytophaga species, and Actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival and tissue destruction. J Dent Res 1984;63:412-21.
96. Nakamura T, Shibata Y, Shimura R, Fujimura S. Isolation and properties of the Capnocytophaga ochracea bacteriocin. Oral Microbiol Immunol 1992;7:96-9.
97. Novák J, Novak L, Shah GR, Woodruff WA, Caufield PW. Transposon mutagenesis: Cloning of chromosomal DNA from the site of Tn916 insertion using polymerase chain reaction. Biotechnol Tech 1997;11:51-4.
98. Gutierrez JA, Crowly PJ, Brown DP, Hillman JD, Youngman P, Bleiweis AS. Insertional mutagenesis and recovery of interrupted genes of Streptococcus mutans by using transposon Tn917: Preliminary characterization of mutants acid sensitivity and nutritional requirements. J Bacteriol 1996;178:4166-75.
99. Ike Y, Clewell DB, Segarra RA, Gilmore MS. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant: Tn916 insertional mutagenesis and cloning. J Bacteriol 1990;172:155-63.
100. de Vos WM, Kuiper OP, van der Meer JR, Siezen RJ. Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by Gram-positive bacteria. Mol Microbiol 1995;17:427-37.
101. Hillman JD, Socransky SS. Replacement therapy for the prevention of dental disease. Adv Dent Res 1987;1:119-25.
102. Jett BD, Gilmore MS. The growth-inhibitory effect of the Enterococcus faecalis bacteriocin encoded by pAD1 extends to the oral streptococci. J Dent Res 1990;69:1640-5.
103. Kitamura K, Masuda N, Kato K, Sobue S, Hamada S. Effect of a bacteriocin-producing strain of Streptococcus sobrinus on infection and establishment of Streptococcus mutans on tooth surfaces in rats. Oral Microbiol Immunol 1989;4:65-70.
104. Svanberg M, Loesche WJ. Implantation of Streptococcus mutans on tooth surface in man. Arch Oral Biol 1978;23:551-6.
105. Köhler B, Bratthall D, Krasse B. Preventive measures in mothers influence the establishment of the bacterium Streptococcus mutans in their infants. Arch Oral Biol 1983;28:225-31.
106. Caufield PW, Cutter G, Dasanyake A. Initial acquisition of mutans streptococci by infants: evidence for a discrete window of infectivity. J Dent Res 1993;72:37-45.
107. Hillman JD, Yaphe BI, Johnson KP. Colonization of the human oral cavity by a strain of Streptococcus mutans. J Dent Res 1985;64:1272-4.
108. Hillman JD, Dzuback AL, Andrews SW. Colonization of the human oral cavity by a Streptococcus mutant mutant producing increased bacteriocin. J Dent Res 1987;66:1092-4.
109. Tanzer JM, Kurasz AB, Clive J. Competitive displacement of mutans streptococci and inhibition of tooth decay by Streptococcus salivarius TOVE-R. Infect Immun 1985;48:44-50.
110. Tanzer JM, Kurasz AB, Clive J. Inhibition of ecological emergence of mutans streptococci naturally transmitted between rats and consequent caries inhibition by Streptococcus salivarius TOVE-R infection. Infect Immun 1985;49:76-83.
111. Kurasz AB, Tanzer JM, Bazer L, Savoldi E. In vitro studies of growth and competition between Streptococcus salivarius TOVE-R and mutans streptococci. J Dent Res 1986;65:1149-53.
112. Hirasawa M, Yamaguchi S, Imanami T, Matsue I, Ikeda T. Effect of mouthrinse containing a bacteriocin from Streptococcus mutans on plaque microflora. J Dent Res 1984;63:298.
113. Fitzgerald RJ, Morhart RE, Marguez C, Adams BO. Inhibition of caries in hamsters treated with staphylococcin 1580. Infect Immun 1986;54:288-90.
114. James SM, Tagg JR. The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci. New Zealand Dent J 1991;87:80-3.
115. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science 1994;264:371-3.
116. Richardson MD. Opportunistic and pathogenic fungi. J Antimicrobial Chemother 1991;28(Suppl A):1-11.
117. Odds FC. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrobial Agents 1996;6:145-7.
118. Berkelman RL, Bryan RT, Osterholm MT, LeDuc JW, Hughes JM. Infectious disease surveillance: A crumbling foundation. Science 1994;264:368-70.
119. Farkas-Himsley H. Bacteriocins-are they broad-spectrum antibiotics?. J Antimicrob Chemother 1980;6:424-6.
120. Isari AM. Implications of the bacteriocinogenic factor in different biological systems: recent advances. Arch Roum Pathol Exper Microbiol 1983;42:31-44.
121. Blondelle SE, Perez-Paya E, Houghten RA. Synthetic combinatorial libraries: Novel discovery strategy for identification of antimicrobial agents. Antimicrob Agents Chemother 1996;40:1067-71.
122. Zuo Y, Xu T, Troxler RF, Li J, Driscoll J, Oppenheim FG. Recombinant histatins: functional domain duplication enhances candacidal activity. Gene 1995;161:87-91.